Metz Tumor Progress Express (Issue 008)

：，

：，

（007）（007）（007）

1.

1.

In this study, Derya et al.

Studies have shown that prostate cancer patients with pN1 or pGleason scores of 8-10 and pT3/4 may consider adjuvant radiotherapy, which is expected to significantly reduce their risk of all-cause death

For details, refer to: JCO: Prostate cancer patients with high risk of recurrence/death may be consolidated with adjuvant radiotherapy after radical resection

Reference for details: Reference for details: Reference for details:JCO: Prostate cancer patients with high risk of recurrence/death may be consolidated by adjuvant radiotherapy after radical resection

2.

2.

Although NRG1 gene fusion is a carcinogenic driving factor for many types of tumors, including lung cancer, it is difficult to study because it is relatively rare

From June 2018 to February 2020, a consortium of 22 centers from 9 countries in Europe, subgroups, and the United States provided pathologically verified data on lung cancer patients carrying NRG1 gene fusion, including DNA and or RNA-based second-generation sequencing data and fluorescence in situ hybridization

The results show that NRG1 gene fusion-positive lung cancer is more heterogeneous than previously recognized molecularly, pathologically and clinically

For details refer to: JCO: Clinicopathological characteristics of NRG1 fusion-positive lung cancer and its response to various treatments.

3.

Previous studies have shown that HER2 amplification/overexpression is observed in approximately 20-25% of breast cancer patients, and it is significantly related to the poor prognosis of patients

However, not all patients with HER2-positive breast cancer respond to Herceptin-based treatment regimens

The results of this study revealed that by disrupting the negative feedback inhibition of FOXO3a-miRNA, it can mediate the abnormal activation of the IGF2/IGF-1R/IRS1 signaling pathway in Herceptin-resistant breast cancer

For details refer to: Nat Commun: FOXO3a-miRNA negative feedback inhibition affects Herceptin resistance in HER2-positive breast cancer.
For details refer to: Nat Commun: FOXO3a-miRNA negative feedback inhibition affects Herceptin resistance in HER2-positive breast cancerFor more information: Formore information: Formore information:Nat Commun: FOXO3a-miRNA negative feedback inhibition affects Herceptin resistance in HER2-positive breast cancer

4.
Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer

4.
Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer 4.
Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer

It is estimated that nearly two-thirds of NSCLC patients show local or remote metastasis of the disease at the time of diagnosis , and only about 15% of patients with metastatic NSCLC can survive 5 years or more after metastasis
.
Although there have been great advances in the treatment of this disease, the response rate of patients with metastatic NSCLC to anticancer therapy is still unsatisfactory, and the tumor recurrence rate after treatment is quite high
.

It is estimated that nearly two-thirds of NSCLC patients show local or remote metastasis of the disease at the time of diagnosis , and only about 15% of patients with metastatic NSCLC can survive 5 years or more after metastasis
.
Although there have been great advances in the treatment of this disease, the response rate of patients with metastatic NSCLC to anticancer therapy is still unsatisfactory, and the tumor recurrence rate after treatment is quite high
.
It is estimated that nearly two-thirds of NSCLC patients show local or remote metastasis of the disease at the time of diagnosis , and only about 15% of patients with metastatic NSCLC can survive 5 years or more after metastasis
.
Although there have been great advances in the treatment of this disease, the response rate of patients with metastatic NSCLC to anticancer therapy is still unsatisfactory, and the tumor recurrence rate after treatment is quite high
.

Therefore, understanding the causes of clinical difficulties of the disease and identifying effective therapeutic targets or prognostic biomarkers is very important for the early identification of metastatic NSCLC
.
Previous studies have shown that Notch signaling is involved in a key mechanism that mediates cancer metastasis and stem cell characteristics
.

stem cell

This study aims to understand how Notch signaling is overactivated to participate in tumor metastasis and self-renewal in NSCLC cells
.
Researchers found that RFC4 (a DNA replication factor amplified in more than 40% of NSCLC tissues) can directly bind to NICD1 (Notch1 intracellular domain) and competitively eliminate CDK8/FBXW7-mediated degradation of NICD1
.

This study aims to understand how Notch signaling is overactivated to participate in tumor metastasis and self-renewal in NSCLC cells
.
This study aims to understand how Notch signaling is overactivated to participate in tumor metastasis and self-renewal in NSCLC cells
.

The results of this study show that the positive feedback loop between RFC4 and NICD1 plays a key role in the metastasis and stem cell characteristics of NSCLC, and reveals its diagnostic and prognostic potential in the treatment of NSCLC
.

The results of this study show that the positive feedback loop between RFC4 and NICD1 plays a key role in the metastasis and stem cell characteristics of NSCLC, and reveals its diagnostic and prognostic potential in the treatment of NSCLC
.
The positive feedback loop between RFC4 and NICD1 plays a key role in the metastasis and stem cell characteristics of NSCLC, and reveals its diagnostic and prognostic potential in the treatment of NSCLC
.

For details, please refer to: Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer

For more information: For more information: For more information: For more information: Formore information:Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer

5.
NEJM: Sotorasib treatment of KRASp.
G12C mutation advanced non-small cell lung cancer phase II clinical data is gratifying

5.
NEJM: Sotorasib treatment of KRASp.
G12C mutant advanced non-small cell lung cancer Phase II clinical data gratifying 5.
NEJM: Sotorasib treatment of KRASp.
G12C mutant advanced non-small cell lung cancer Phase II clinical data gratifying

Sotorasib is the first KRAS inhibitor to enter clinical trials.
In a phase I clinical study, Sotorasib showed anti-cancer activity in patients with advanced solid tumors with KRASp.
G12C mutations, and was observed in a subgroup of patients with non-small cell lung cancer (NSCLC) Pleasant anti-cancer activity
.
Researchers recently announced the Phase II clinical study data of Sotorasib in the treatment of patients with advanced NSCLC with KRAS p.
G12C mutation
.

Sotorasib is the first KRAS inhibitor to enter clinical trials.
In a phase I clinical study, Sotorasib showed anti-cancer activity in patients with advanced solid tumors with KRASp.
G12C mutations, and was observed in a subgroup of patients with non-small cell lung cancer (NSCLC) Pleasant anti-cancer activity
.
Researchers recently announced the Phase II clinical study data of Sotorasib in the treatment of patients with advanced NSCLC with KRAS p.
G12C mutation
.
Sotorasib is the first KRAS inhibitor to enter clinical trials.
In a phase I clinical study, Sotorasib showed anti-cancer activity in patients with advanced solid tumors with KRASp.
G12C mutations, and was observed in a subgroup of patients with non-small cell lung cancer (NSCLC) Pleasant anti-cancer activity
.
Researchers recently announced the Phase II clinical study data of Sotorasib in the treatment of patients with advanced NSCLC with KRAS p.
G12C mutation
.

In this single-center phase II trial, the researchers investigated the efficacy of Sotorasib on patients with advanced NSCLC with KRAS p.
G12C mutation who had previously received standard treatment.
The patients received 960 mg of the drug once a day
.
The primary endpoint of the study is objective response (complete or partial response), and key secondary endpoints include response duration, disease control (defined as complete response, partial response or stable disease), progression-free survival, overall survival, and safety
.

In this single-center phase II trial, the researchers investigated the efficacy of Sotorasib on patients with advanced NSCLC with KRAS p.
G12C mutation who had previously received standard treatment.
The patients received 960 mg of the drug once a day
.
The primary endpoint of the study is objective response (complete or partial response), and key secondary endpoints include response duration, disease control (defined as complete response, partial response or stable disease), progression-free survival, overall survival, and safety
.
In this single-center phase II trial, the researchers investigated the efficacy of Sotorasib on patients with advanced NSCLC with KRAS p.
G12C mutation who had previously received standard treatment.
The patients received 960 mg of the drug once a day
.
The primary endpoint of the study is objective response (complete or partial response), and key secondary endpoints include response duration, disease control (defined as complete response, partial response or stable disease), progression-free survival, overall survival, and safety
.
In this single-center phase II trial, the researchers investigated the efficacy of Sotorasib on patients with advanced NSCLC with KRAS p.
G12C mutation who had previously received standard treatment.
The patients received 960 mg of the drug once a day
.
The primary endpoint of the study is objective response (complete or partial response), and key secondary endpoints include response duration, disease control (defined as complete response, partial response or stable disease), progression-free survival, overall survival, and safety
.

Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy
.

Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy
.
Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy
.
Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy
.
Sotorasib has shown good therapeutic effect and good safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy.
Sotorasib has shown good efficacy and safety in KRASp.
G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy.
Good treatment effect and good safety in patients

For details, please refer to: NEJM: Sotorasib treatment of KRASp.
G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying

For details refer to: NEJM: Sotorasib treatment of KRASp.
G12C mutation advanced non-small cell lung cancer Phase II clinical data is gratifying For details refer to: NEJM: Sotorasib treatment of KRASp.
G12C mutation advanced non-small cell lung cancer Phase II clinical data is gratifying Fordetails refer to:NEJM: Sotorasib treatment of KRASp .
G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying.
Fordetails, please refer to: Fordetails reference:NEJM: Sotorasib in the treatment of KRASp.
G12C mutant advanced non-small cell lung cancer Phase II clinical data are gratifying

6.
JAMA Oncol: Efficacy and safety of Pembrolizumab combined with concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799

6.
JAMA Oncol: Pembrolizumab (Pembrolizumab) combined with concurrent chemotherapy and radiotherapy (cCRT) in the treatment of unresectable stage III NSCLC efficacy and safety: KEYNOTE-799 6.
JAMA Oncol: Pembrolizumab (Pembrolizumab) combination Efficacy and safety of concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799

KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries
.
The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints were overall survival (OS), progression-free survival (PFS) and safety
.
A total of 216 patients were enrolled in the study, of which 112 patients entered cohort A (squamous cell carcinoma and non-squamous cell carcinoma NSCLC) and 104 patients entered cohort B (non-squamous carcinoma NSCLC)
.
There are 76 males in cohort A patients [67.
9%], and the median age is 66.
0 years [46-90]; there are 62 patients in cohort B patients [60.
8%], and the median age is 64.
0 years [35-81]
.

KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries
.
The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints were overall survival (OS), progression-free survival (PFS) and safety
.
A total of 216 patients were enrolled in the study, of which 112 patients entered cohort A (squamous cell carcinoma and non-squamous cell carcinoma NSCLC) and 104 patients entered cohort B (non-squamous carcinoma NSCLC)
.
There are 76 males in cohort A patients [67.
9%], and the median age is 66.
0 years [46-90]; there are 62 patients in cohort B patients [60.
8%], and the median age is 64.
0 years [35-81]
.
KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries
.
The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints were overall survival (OS), progression-free survival (PFS) and safety
.
A total of 216 patients were enrolled in the study, of which 112 patients entered cohort A (squamous cell carcinoma and non-squamous cell carcinoma NSCLC) and 104 patients entered cohort B (non-squamous carcinoma NSCLC)
.
There are 76 males in cohort A patients [67.
9%], and the median age is 66.
0 years [46-90]; there are 62 patients in cohort B patients [60.
8%], and the median age is 64.
0 years [35-81]
.

Studies believe that Pembrolizumab combined with concurrent radiotherapy and chemotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC, and the toxicity is controllable
.

Studies believe that Pembrolizumab combined with concurrent radiotherapy and chemotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC, and the toxicity is controllable
.
Studies believe that Pembrolizumab combined with concurrent radiotherapy and chemotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC, and the toxicity is controllable
.
Studies believe that Pembrolizumab combined with concurrent radiotherapy and chemotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC, and the toxicity is controllable
.
Studies believe that Pembrolizumab combined with concurrent radiotherapy and chemotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC, and the toxicity is controllable
.

For details, please refer to: JAMA Oncol: Efficacy and safety of Pembrolizumab combined with concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799

For details, refer to: JAMA Oncol: Efficacy and safety of Pembrolizumab combined with concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799 For details: JAMA Oncol: Pembrolizumab ) Efficacy and safety of combined concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799 Fordetails: Fordetails: Fordetails: Fordetails: Fordetails:JAMA Oncol: Pembrolizumab (Pembrolizumab) Efficacy and safety of combined concurrent radiotherapy and chemotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799JAMA Oncol: Efficacy of Pembrolizumab (Pembrolizumab) combined with concurrent radiotherapy and chemotherapy (cCRT) in the treatment of unresectable stage III NSCLC And safety: KEYNOTE-799

7.
JCO: Residual after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)

7.
JCO: Residual after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131) 7.
JCO: triple-negative breast cancer (TNBC) Patients who remain after neoadjuvant chemotherapy, the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)

A foreign research team conducted a randomized phase III study EA1131 to evaluate the residual after neoadjuvant chemotherapy in patients with basal type TNBC, and the postoperative application of platinum-based adjuvant chemotherapy to compare the efficacy of postoperative capecitabine adjuvant chemotherapy.
The relevant results were published in the Journal of Clinical Oncology On
.

A foreign research team conducted a randomized phase III study EA1131 to evaluate the residual after neoadjuvant chemotherapy in patients with basal type TNBC, and the postoperative application of platinum-based adjuvant chemotherapy to compare the efficacy of postoperative capecitabine adjuvant chemotherapy.
The relevant results were published in the Journal of Clinical Oncology On
.
A foreign research team conducted a randomized phase III study EA1131 to evaluate the residual after neoadjuvant chemotherapy in patients with basal type TNBC, and the postoperative application of platinum-based adjuvant chemotherapy to compare the efficacy of postoperative capecitabine adjuvant chemotherapy.
The relevant results were published in the Journal of Clinical Oncology On
.

The study is a randomized phase III study, including II or III TNBC, neoadjuvant chemotherapy with residual lesions greater than or equal to 1 cm, postoperative random allocation to receive platinum-based chemotherapy group and capecitabine group, platinum-based chemotherapy is There is a cycle every 21 days for a total of 4 cycles; while capecitabine is taken for 14 days with 7 days of rest, for a total of 6 cycles
.
TNBC performs basal and non-basal delamination analysis
.
Mainly conduct non-inferiority verification to prove that postoperative platinum-based chemotherapy is non-inferior or superior to capecitabine
.

The study is a randomized phase III study, including II or III TNBC, neoadjuvant chemotherapy with residual lesions greater than or equal to 1 cm, postoperative random allocation to receive platinum-based chemotherapy group and capecitabine group, platinum-based chemotherapy is There is a cycle every 21 days for a total of 4 cycles; while capecitabine is taken for 14 days with 7 days of rest, for a total of 6 cycles
.
TNBC performs basal and non-basal delamination analysis
.
Mainly conduct non-inferiority verification to prove that postoperative platinum-based chemotherapy is non-inferior or superior to capecitabine
.
The study is a randomized phase III study, including II or III TNBC, neoadjuvant chemotherapy with residual lesions greater than or equal to 1 cm, postoperative random allocation to receive platinum-based chemotherapy group and capecitabine group, platinum-based chemotherapy is There is a cycle every 21 days for a total of 4 cycles; while capecitabine is taken for 14 days with 7 days of rest, for a total of 6 cycles
.
TNBC performs basal and non-basal delamination analysis
.
Mainly conduct non-inferiority verification to prove that postoperative platinum-based chemotherapy is non-inferior or superior to capecitabine
.

Studies believe that compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC)
.
Moreover, platinum-based chemotherapy has more severe toxicity than capecitabine
.

Studies believe that compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC)
.
Moreover, platinum-based chemotherapy has more severe toxicity than capecitabine
.
Studies believe that compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC)
.
Moreover, platinum-based chemotherapy has more severe toxicity than capecitabine
.
Studies believe that compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC)
.
Moreover, platinum-based chemotherapy has more severe toxicity than capecitabine
.
Studies believe that compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC)
.
Moreover, platinum-based chemotherapy has more severe toxicity than capecitabine
.

For details, refer to: JCO: Residual after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)

For details, refer to: JCO: Residual after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131) For details: JCO:Three-negative Breast cancer (TNBC) patients remain after neoadjuvant chemotherapy, the efficacy and safety of platinum-based chemotherapy compared with capecitabine: a randomized phase III study (ECOG-ACRIN EA1131) fordetails: Fordetails: Fordetails: Fordetails: Fordetails:JCO: Residual after neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)JCO: neoadjuvant for patients withtriplenegative breast cancer (TNBC) Residual after chemotherapy, the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)

8.
Cancers: Neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC)

8.
Cancers: Neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC) 8.
Cancers: Neutrophil/lymphocyte ratio (NLR) is a metaphase hepatocyte Prognostic indicators of first-line TACE treatment for patients with cancer (HCC)

A research team from South Korea conducted a retrospective study to evaluate the prognostic value of first-line TACE for NLR in patients with initial untreated interim HCC
.
The results were published in Cancers magazine
.

A research team from South Korea conducted a retrospective study to evaluate the prognostic value of first-line TACE for NLR in patients with initial untreated interim HCC
.
The results were published in Cancers magazine
.
A research team from South Korea conducted a retrospective study to evaluate the prognostic value of first-line TACE for NLR in patients with initial untreated interim HCC
.
The results were published in Cancers magazine
.

The study retrospectively included patients with interim HCC who were initially untreated from 2008 to 2017 and received TACE treatment in the first line
.
Patients before 2013 were assigned to the study cohort, and patients after 2013 were assigned to the verification cohort
.
The main research endpoint is the relationship between NLR and OS (after adjusting for related factors)
.
The secondary endpoint was the response 6 months after NLR and TACE treatment
.
The study finally included 931 patients, including 495 patients in the study cohort and 436 patients in the verification cohort
.
Except for age, the basic characteristics of the two cohorts are similar
.

The study retrospectively included patients with interim HCC who were initially untreated from 2008 to 2017 and received TACE treatment in the first line
.
Patients before 2013 were assigned to the study cohort, and patients after 2013 were assigned to the verification cohort
.
The main research endpoint is the relationship between NLR and OS (after adjusting for related factors)
.
The secondary endpoint was the response 6 months after NLR and TACE treatment
.
The study finally included 931 patients, including 495 patients in the study cohort and 436 patients in the verification cohort
.
Except for age, the basic characteristics of the two cohorts are similar
.
The study retrospectively included patients with interim HCC who were initially untreated from 2008 to 2017 and received TACE treatment in the first line
.
Patients before 2013 were assigned to the study cohort, and patients after 2013 were assigned to the verification cohort
.
The main research endpoint is the relationship between NLR and OS (after adjusting for related factors)
.
The secondary endpoint was the response 6 months after NLR and TACE treatment
.
The study finally included 931 patients, including 495 patients in the study cohort and 436 patients in the verification cohort
.
Except for age, the basic characteristics of the two cohorts are similar
.

Studies have shown that the neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC), and a high NLR indicates poor survival
.

Studies have shown that the neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC), and a high NLR indicates poor survival
.
Studies have shown that the neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC), and a high NLR indicates poor survival
.
The neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC), and a high NLR indicates poor survival
.
The neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC), and a high NLR indicates poor survival
.

For details, please refer to: Cancers: Neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC)

For details, please refer to: Cancers: Neutrophil/lymphocyte ratio (NLR) is a prognostic indicator of first-line TACE treatment for patients with metaphase hepatocellular carcinoma (HCC).
For details, please refer to: Cancers: Neutrophil/lymphocyte ratio (NLR) is metaphase Fordetailsof prognostic indicatorsforfirst-line hepatocellular carcinoma (HCC) patients receiving TACE treatment: Fordetails: Fordetails: Fordetails: Fordetails:Cancers: Neutrophil/lymphocyte ratio (NLR) is the first line for patients with metaphase hepatocellular carcinoma (HCC) Prognostic indicators of TACE treatment

9.
Eur Urol Oncol: androgen blockade therapy combined with docetaxel to treat high-risk biochemical recurrence of prostate cancer

9.
Eur Urol Oncol: androgen blockade therapy combined with docetaxel for high-risk biochemical recurrence of prostate cancer 9.
Eur Urol Oncol: androgen blockade therapy combined with docetaxel for high-risk biochemical recurrence of prostate cancer

There is currently no standard treatment for patients with high-risk biochemical recurrence (BCR) after prostatectomy
.
Recently, researchers have evaluated whether adding docetaxel to androgen-blocking therapy (ADT) can improve the progression-free survival (PFS) of patients with high-risk BCR
.

There is currently no standard treatment for patients with high-risk biochemical recurrence (BCR) after prostatectomy
.
Recently, researchers have evaluated whether adding docetaxel to androgen-blocking therapy (ADT) can improve the progression-free survival (PFS) of patients with high-risk BCR
.
There is currently no standard treatment for patients with high-risk biochemical recurrence (BCR) after prostatectomy
.
Recently, researchers have evaluated whether adding docetaxel to androgen-blocking therapy (ADT) can improve the progression-free survival (PFS) of patients with high-risk BCR
.

TAX3503 is a multicenter phase 3 trial that randomizes high-risk BCR patients for 18 months of ADT treatment (with or without docetaxel) (75mg/m2 q3w, 10 cycles)
.
The inclusion criteria included prostate-specific antigen (PSA) ≥1.
0ng/ml after simple prostatectomy or postoperative radiotherapy, PSA doubling time ≤9 months, and no metastasis found on computed tomography and bone scans
.
The primary endpoint of the study was PFS after testosterone returned to non-castrated levels (testosterone >50ng/dl)
.
Secondary endpoints include time to testosterone recovery, overall survival (OS), quality of life, and safety
.

TAX3503 is a multicenter phase 3 trial that randomizes high-risk BCR patients for 18 months of ADT treatment (with or without docetaxel) (75mg/m2 q3w, 10 cycles)
.
The inclusion criteria included prostate-specific antigen (PSA) ≥1.
0ng/ml after simple prostatectomy or postoperative radiotherapy, PSA doubling time ≤9 months, and no metastasis found on computed tomography and bone scans
.
The primary endpoint of the study was PFS after testosterone returned to non-castrated levels (testosterone >50ng/dl)
.
Secondary endpoints include time to testosterone recovery, overall survival (OS), quality of life, and safety
.
TAX3503 is a multicenter phase 3 trial that randomizes high-risk BCR patients for 18 months of ADT treatment (with or without docetaxel) (75mg/m2 q3w, 10 cycles)
.
The inclusion criteria included prostate-specific antigen (PSA) ≥1.
0ng/ml after simple prostatectomy or postoperative radiotherapy, PSA doubling time ≤9 months, and no metastasis found on computed tomography and bone scans
.
The primary endpoint of the study was PFS after testosterone returned to non-castrated levels (testosterone >50ng/dl)
.
Secondary endpoints include time to testosterone recovery, overall survival (OS), quality of life, and safety
.

Studies believe that TAX3503 has not proven that adding docetaxel to the ADT treatment of high-risk BCR patients has a significant benefit
.
In addition, the recovery of testosterone is not affected by the addition of docetaxel to ADT treatment
.

Studies believe that TAX3503 has not proven that adding docetaxel to the ADT treatment of high-risk BCR patients has a significant benefit
.
In addition, the recovery of testosterone is not affected by the addition of docetaxel to ADT treatment
.
Studies believe that TAX3503 has not proven that adding docetaxel to the ADT treatment of high-risk BCR patients has a significant benefit
.
In addition, the recovery of testosterone is not affected by the addition of docetaxel to ADT treatment
.
TAX3503 does not prove that the addition of docetaxel to the ADT treatment of high-risk BCR patients has significant benefits.
Testosterone recovery is not affected by the addition of docetaxel to ADT treatment.

For details, please refer to: Eur Urol Oncol: Combination of Androgen Blocking Therapy and Docetaxel to Treat High Risk Biochemical Recurrence of Prostate Cancer

For details, refer to: Eur Urol Oncol: Combination of androgen blockade therapy and docetaxel for high-risk biochemical recurrence of prostate cancer.
For details refer to: Eur Urol Oncol: Combination of androgen blockade therapy and docetaxel for high-risk biochemical recurrence Fordetails ofprostate cancer: Fordetails: Fordetails: Fordetails: Fordetails:Eur Urol Oncol: Androgen blockade therapy combined with docetaxel to treat high-risk biochemical recurrence of prostate cancer

10.
JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)

10.
JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs) 10.
JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)

A research team from Canada conducted a retrospective study to evaluate the cumulative incidence of tumor-specific and non-tumor deaths in patients with neuroendocrine tumors (NETs)
.
Related research results were published in the Journal of the National Comprehensive Cancer Network (JNCCN)
.

A research team from Canada conducted a retrospective study to evaluate the cumulative incidence of tumor-specific and non-tumor deaths in patients with neuroendocrine tumors (NETs)
.
Related research results were published in the Journal of the National Comprehensive Cancer Network (JNCCN)
.
A research team from Canada conducted a retrospective study to evaluate the cumulative incidence of tumor-specific and non-tumor deaths in patients with neuroendocrine tumors (NETs)
.
Related research results were published in the Journal of the National Comprehensive Cancer Network (JNCCN)
.

The study is a population-based retrospective cohort study that included patients with NETs registered in Canada from 2001 to 2015
.
To evaluate the cumulative incidence of tumor-specific death and non-tumor death in patients with primary NETs and different metastatic states
.
A total of 8607 patients were enrolled in the study, with a median follow-up of 42 months (range: 17-82 months)
.
The most common primary tumor site was bronchopulmonary (22.
8%), followed by the small intestine (19.
3%) and rectum (14.
4%)
.
42.
2% of patients had metastases, including 32.
0% of patients had concurrent metastases
.

The study is a population-based retrospective cohort study that included patients with NETs registered in Canada from 2001 to 2015
.
To evaluate the cumulative incidence of tumor-specific death and non-tumor death in patients with primary NETs and different metastatic states
.
A total of 8607 patients were enrolled in the study, with a median follow-up of 42 months (range: 17-82 months)
.
The most common primary tumor site was bronchopulmonary (22.
8%), followed by the small intestine (19.
3%) and rectum (14.
4%)
.
42.
2% of patients had metastases, including 32.
0% of patients had concurrent metastases
.
The study is a population-based retrospective cohort study that included patients with NETs registered in Canada from 2001 to 2015
.
To evaluate the cumulative incidence of tumor-specific death and non-tumor death in patients with primary NETs and different metastatic states
.
A total of 8607 patients were enrolled in the study, with a median follow-up of 42 months (range: 17-82 months)
.
The most common primary tumor site was bronchopulmonary (22.
8%), followed by the small intestine (19.
3%) and rectum (14.
4%)
.
42.
2% of patients had metastases, including 32.
0% of patients had concurrent metastases
.
The most common primary tumor site was bronchopulmonary (22.
8%), followed by the small intestine (19.
3%) and rectum (14.
4%)
.

Studies have concluded that the overall population of neuroendocrine tumors (NETs) has a higher risk of tumor-specific death than non-tumor-related deaths
.
There is strong heterogeneity in patients with tumors in different parts
.
For patients with non-metastatic gastrointestinal NETs, ​​non-tumor-related mortality is higher than tumor-specific death
.

Studies have shown that the overall population of neuroendocrine tumors (NETs) has a higher risk of tumor-specific death than non-tumor-related deaths
.
There is strong heterogeneity in patients with tumors in different parts
.
For patients with non-metastatic gastrointestinal NETs, ​​non-tumor-related mortality is higher than tumor-specific death
.
Studies have concluded that the overall population of neuroendocrine tumors (NETs) has a higher risk of tumor-specific death than non-tumor-related deaths
.
There is strong heterogeneity in patients with tumors in different parts
.
For patients with non-metastatic gastrointestinal NETs, ​​non-tumor-related mortality is higher than tumor-specific death
.
Patients with neuroendocrine tumors (NETs) have a higher risk of tumor-specific death than non-tumor-related deaths
.
There is strong heterogeneity in patients with tumors in different parts
.
For patients with non-metastatic gastrointestinal NETs, ​​non-tumor-related mortality is higher than tumor-specific death
.
Patients with neuroendocrine tumors (NETs) have a higher risk of tumor-specific death than non-tumor-related deaths
.
There is strong heterogeneity in patients with tumors in different parts
.
For patients with non-metastatic gastrointestinal NETs, ​​non-tumor-related mortality is higher than tumor-specific death
.

For details, please refer to: JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)

Details Reference: JNCCN: neuroendocrine tumors (NETs) patient-specific cancer mortality risk details Reference: JNCCN: risk neuroendocrine tumors (NETs) in patients with tumor-specific deathdetails Reference:Reference Guide:Reference Guide:Reference Guide:JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)

 

Leave a message here